TG Therapeutics (NASDAQ:TGTX) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Monday, September 17th.
TGTX has been the subject of a number of other research reports. BidaskClub lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, June 12th. Zacks Investment Research upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. Finally, HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of TG Therapeutics in a research note on Tuesday, August 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $26.00.
Shares of TG Therapeutics stock traded up $0.08 during trading hours on Monday, reaching $5.58. The stock had a trading volume of 1,808,339 shares, compared to its average volume of 1,377,200. The company has a market cap of $463.78 million, a price-to-earnings ratio of -2.92 and a beta of 1.35. TG Therapeutics has a 1 year low of $4.95 and a 1 year high of $17.35.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). TG Therapeutics had a negative net margin of 97,412.51% and a negative return on equity of 177.79%. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. Analysts expect that TG Therapeutics will post -2.15 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of TGTX. venBio Select Advisor LLC grew its stake in TG Therapeutics by 58.7% during the 1st quarter. venBio Select Advisor LLC now owns 5,229,619 shares of the biopharmaceutical company’s stock valued at $74,261,000 after purchasing an additional 1,935,156 shares in the last quarter. RA Capital Management LLC grew its stake in TG Therapeutics by 73.1% during the 2nd quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock valued at $56,266,000 after purchasing an additional 1,806,452 shares in the last quarter. Wells Fargo & Company MN grew its stake in TG Therapeutics by 2,148.1% during the 2nd quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock valued at $11,686,000 after purchasing an additional 849,233 shares in the last quarter. BlackRock Inc. grew its stake in TG Therapeutics by 17.4% during the 2nd quarter. BlackRock Inc. now owns 4,081,050 shares of the biopharmaceutical company’s stock valued at $53,667,000 after purchasing an additional 605,844 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in TG Therapeutics during the 1st quarter valued at approximately $8,574,000. Hedge funds and other institutional investors own 48.99% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Recommended Story: Average Daily Trade Volume Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.